Published in Breast J on May 19, 2003
A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med (2003) 13.81
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst (2005) 5.55
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
HER-2 testing in breast cancer using parallel tissue-based methods. JAMA (2004) 4.60
Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med (2012) 3.86
Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol (2008) 3.40
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2009) 3.17
NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis. J Natl Compr Canc Netw (2009) 2.78
Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol (2009) 2.61
Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma? Am J Surg (2005) 2.47
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.41
Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol (2007) 2.35
Trends in incidence rates of invasive lobular and ductal breast carcinoma. JAMA (2003) 2.24
Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol (2012) 2.20
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol (2005) 2.19
Management of the neck after chemoradiotherapy for head and neck cancers in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.12
Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol (2006) 2.12
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations. Am J Clin Pathol (2003) 2.07
Changes in blood flow and metabolism in locally advanced breast cancer treated with neoadjuvant chemotherapy. J Nucl Med (2003) 2.06
Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol (2007) 1.93
Guideline implementation for breast healthcare in low- and middle-income countries: early detection resource allocation. Cancer (2008) 1.90
Relationship between menopausal hormone therapy and risk of ductal, lobular, and ductal-lobular breast carcinomas. Cancer Epidemiol Biomarkers Prev (2008) 1.88
Blood flow and metabolism in locally advanced breast cancer: relationship to response to therapy. J Nucl Med (2002) 1.87
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
p27(Kip1) and cyclin E expression and breast cancer survival after treatment with adjuvant chemotherapy. J Natl Cancer Inst (2006) 1.74
Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10. J Clin Oncol (2008) 1.69
Breast cancer version 3.2014. J Natl Compr Canc Netw (2014) 1.63
Breast pathology guideline implementation in low- and middle-income countries. Cancer (2008) 1.61
Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. J Clin Oncol (2004) 1.61
Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol (2008) 1.60
Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol (2007) 1.59
Breast Cancer Version 2.2015. J Natl Compr Canc Netw (2015) 1.59
Adjuvant vinorelbine and cisplatin in elderly patients: National Cancer Institute of Canada and Intergroup Study JBR.10. J Clin Oncol (2007) 1.57
Chromosome 17 polysomy without human epidermal growth factor receptor 2 amplification does not predict response to lapatinib plus paclitaxel compared with paclitaxel in metastatic breast cancer. Clin Cancer Res (2010) 1.57
Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol (2011) 1.56
Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease. J Thorac Cardiovasc Surg (2004) 1.52
Serial 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) to monitor treatment of bone-dominant metastatic breast cancer predicts time to progression (TTP). Breast Cancer Res Treat (2007) 1.48
Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April, 2007. Breast J (2009) 1.48
Invasive breast cancer. J Natl Compr Canc Netw (2011) 1.43
The relation of reproductive factors to mortality from breast cancer. Cancer Epidemiol Biomarkers Prev (2002) 1.42
Would the real breast cancer please stand up? A global perspective of breast cancer. Breast (2008) 1.42
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol (2005) 1.41
Costs and health effects of breast cancer interventions in epidemiologically different regions of Africa, North America, and Asia. Breast J (2006) 1.40
Indications for breast MRI in the patient with newly diagnosed breast cancer. J Natl Compr Canc Netw (2009) 1.40
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw (2016) 1.40
Breast cancer management in low resource countries (LRCs): consensus statement from the Breast Health Global Initiative. Breast (2011) 1.39
Problem solving for breast health care delivery in low and middle resource countries (LMCs): consensus statement from the Breast Health Global Initiative. Breast (2011) 1.38
Potential of chemotherapy-herb interactions in adult cancer patients. Support Care Cancer (2004) 1.31
Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol (2002) 1.30
Axillary lymph node dose with tangential breast irradiation. Int J Radiat Oncol Biol Phys (2005) 1.29
Twenty-five years of clinical research for patients with limited-stage small cell lung carcinoma in North America. Cancer (2002) 1.25
Lupus mastitis: radiologic and pathologic features. AJR Am J Roentgenol (2002) 1.24
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.23
Paget disease of the breast: changing patterns of incidence, clinical presentation, and treatment in the U.S. Cancer (2006) 1.21
Combined use of MRI and PET to monitor response and assess residual disease for locally advanced breast cancer treated with neoadjuvant chemotherapy. Acad Radiol (2004) 1.14
Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res (2010) 1.13
PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake. Clin Cancer Res (2011) 1.12
Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat (2011) 1.10
A review of global cancer burden: trends, challenges, strategies, and a role for surgeons. J Surg Oncol (2012) 1.09
Residual tumor uptake of [99mTc]-sestamibi after neoadjuvant chemotherapy for locally advanced breast carcinoma predicts survival. Cancer (2005) 1.09
Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC). Am J Clin Oncol (2004) 1.08
Guideline implementation for breast healthcare in low- and middle-income countries: treatment resource allocation. Cancer (2008) 1.07
Optimized end-stacking provides specificity of N-methyl mesoporphyrin IX for human telomeric G-quadruplex DNA. J Am Chem Soc (2012) 1.07
Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park) (2003) 1.02
Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial. Clin Cancer Res (2009) 1.01
Gastric linitis plastica from metastatic breast carcinoma: FDG and FES PET appearances. AJR Am J Roentgenol (2007) 1.01
Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 0.99
Breast cancer in limited-resource countries: treatment and allocation of resources. Breast J (2006) 0.99
Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer. Clin Cancer Res (2011) 0.98
Survey on a mammographic screening program in Istanbul, Turkey. Breast J (2011) 0.97
An unusual case of multiple giant myelolipomas: clinical and pathogenetic implications. Endocr Pathol (2003) 0.97
Papillary lesions of the breast with and without atypical ductal hyperplasia: can we accurately predict benign behavior from core needle biopsy? Am J Clin Pathol (2004) 0.97
Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat (2006) 0.96
Sequenced compared with simultaneous anthracycline and cyclophosphamide in high-risk stage I and II breast cancer: final analysis from INT-0137 (S9313). J Clin Oncol (2007) 0.96
Treatment of breast cancer in countries with limited resources. Breast J (2003) 0.96
Guidelines for International Breast Health and Cancer Control--Implementation. Introduction. Cancer (2008) 0.95
Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET. Radiographics (2002) 0.95
Identifying important breast cancer control strategies in Asia, Latin America and the Middle East/North Africa. BMC Health Serv Res (2011) 0.95
Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897. J Clin Oncol (2009) 0.92
Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast (2013) 0.92
Invasive breast cancer. J Natl Compr Canc Netw (2007) 0.92
Epithelioid sarcoma: the University of Washington experience. Am J Surg (2008) 0.92
Breast cancer management in middle-resource countries (MRCs): consensus statement from the Breast Health Global Initiative. Breast (2011) 0.91